Objective:

To identify a new class of blood nanoparticles that may improve early diagnosis of Alzheimer’s disease.

Approach:

• Study Design: The study analyzed blood and brain samples from 26 individuals with confirmed Alzheimer’s disease or no evidence of the disease, comparing three classes of extracellular particles.
• Particle Identification: Researchers focused on a new type of particle called 'SECmeres' that carry brain-derived RNA signatures.
• Laboratory Workflow: Introduced a method called SECrifuge to isolate SECmeres efficiently.

Key Findings:

• SECmeres consistently distinguished Alzheimer’s disease from cognitively normal controls.
• SECmeres contained distinct brain-derived RNA markers such as L1CAM, neurogranin, and others.
• The SECrifuge method is more reproducible and cost-effective than traditional ultracentrifugation.

Interpretation:

Limitations:

• The study cohort was small and primarily consisted of White participants.
• Samples were collected post-mortem, limiting applicability to living patients.
• Further research is needed with larger, more diverse cohorts and living patients.

Conclusion:

Sources:

• Nature Communications